Trump Administration Expands Drug Price Deals to 26 Manufacturers

## Catalyst Analysis: Expanded Pharmaceutical Pricing Agreements

On August 31, 2026, the White House announced nine new agreements with pharmaceutical manufacturers, expanding the total number of companies participating in Most-Favored-Nation (MFN) pricing deals to 26. These agreements now encompass 89% of the branded drug market. The deals aim to reduce the net price of new prescription drugs for Americans, aligning them with prices paid in other developed countries.

The nine newly added manufacturers are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These agreements cover drugs for various chronic, costly, and rare diseases, including conditions like hemophilia, Parkinson's disease, and certain cancers. The administration stated that these agreements will also provide State Medicaid programs access to MFN drug prices, potentially leading to significant savings.

Previous actions include an Executive Order signed on May 12, 2025, and letters sent to manufacturers on July 31, 2025. The first agreements were announced on September 30, 2025, with further developments on December 1, 2025, and December 19, 2025.

## Impact on Pharmaceutical Sector

### Winners, Losers & Uncertainty

Companies signing onto the MFN deals may face pressure on profit margins for drugs sold in the U.S. However, the administration also noted commitments from these manufacturers to invest at least $19.6 billion collectively in U.S. manufacturing. Several companies are also donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), aimed at bolstering domestic supply chains.

### Risk Watch

The timeline for the full implementation and the precise financial impact on manufacturers remain subjects for observation. The administration highlighted that since a February launch, patients have saved over $700 million on medicines through TrumpRx, including discounts on obesity and infertility treatments. Senior citizens also gained access to GLP-1 treatments for $50 per month in July 2026, resulting in substantial savings for over 500,000 seniors.